 |
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Cellular component
|
membrane
|
1 term
|
 |
|
Biological process
|
immune response
|
1 term
|
 |
|
Biochemical function
|
tumor necrosis factor receptor binding
|
1 term
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
J Biol Chem
264:17595-17605
(1989)
|
|
PubMed id:
|
|
|
|
|
| |
|
The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding.
|
|
M.J.Eck,
S.R.Sprang.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The three-dimensional structure of tumor necrosis factor (TNF-alpha), a protein
hormone secreted by macrophages, has been determined at 2.6 A resolution by
x-ray crystallography. Phases were determined by multiple isomorphous
replacement using data collected from five heavy atom derivatives. The multiple
isomorphous replacement phases were further improved by real space symmetry
averaging, exploiting the noncrystallographic 3-fold symmetry of the TNF-alpha
trimer. An atomic model corresponding to the known amino acid sequence of
TNF-alpha was readily built into the electron density map calculated with these
improved phases. The 17,350-dalton monomer forms an elongated, antiparallel
beta-pleated sheet sandwich with a "jelly-roll" topology. Three
monomers associate intimately about a 3-fold axis of symmetry to form a compact
bell-shaped trimer. Examination of the model and comparison to known protein
structures reveals striking structural homology to several viral coat proteins,
particularly satellite tobacco necrosis virus. Locations of residues conserved
between TNF-alpha and lymphotoxin (TNF-beta, a related cytokine known to bind to
the same receptors as TNF-alpha) suggest that lymphotoxin, like TNF-alpha, binds
to the receptor as a trimer and that the general site of interaction with the
receptor is at the "base" of the trimer.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
P.Kleinbongard,
R.Schulz,
and
G.Heusch
(2011).
TNFα in myocardial ischemia/reperfusion, remodeling and heart failure.
|
| |
Heart Fail Rev, 16,
49-69.
|
 |
|
|
|
|
 |
L.N.Shingarova,
E.F.Boldyreva,
S.A.Yakimov,
S.V.Guryanova,
D.A.Dolgikh,
S.A.Nedospasov,
and
M.P.Kirpichnikov
(2010).
Novel mutants of human tumor necrosis factor with dominant-negative properties.
|
| |
Biochemistry (Mosc), 75,
1458-1463.
|
 |
|
|
|
|
 |
S.G.Hymowitz,
and
V.M.Dixit
(2010).
Unleashing cell death: the Fas-FADD complex.
|
| |
Nat Struct Mol Biol, 17,
1289-1290.
|
 |
|
|
|
|
 |
S.Yachamaneni,
G.Yushin,
S.H.Yeon,
Y.Gogotsi,
C.Howell,
S.Sandeman,
G.Phillips,
and
S.Mikhalovsky
(2010).
Mesoporous carbide-derived carbon for cytokine removal from blood plasma.
|
| |
Biomaterials, 31,
4789-4794.
|
 |
|
|
|
|
 |
C.Zhan,
Q.Yan,
Y.Patskovsky,
Z.Li,
R.Toro,
A.Meyer,
H.Cheng,
M.Brenowitz,
S.G.Nathenson,
and
S.C.Almo
(2009).
Biochemical and structural characterization of the human TL1A ectodomain.
|
| |
Biochemistry, 48,
7636-7645.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
G.Cai,
and
G.J.Freeman
(2009).
The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.
|
| |
Immunol Rev, 229,
244-258.
|
 |
|
|
|
|
 |
K.Chattopadhyay,
E.Lazar-Molnar,
Q.Yan,
R.Rubinstein,
C.Zhan,
V.Vigdorovich,
U.A.Ramagopal,
J.Bonanno,
S.G.Nathenson,
and
S.C.Almo
(2009).
Sequence, structure, function, immunity: structural genomics of costimulation.
|
| |
Immunol Rev, 229,
356-386.
|
 |
|
|
|
|
 |
S.Haider,
and
M.Knöfler
(2009).
Human tumour necrosis factor: physiological and pathological roles in placenta and endometrium.
|
| |
Placenta, 30,
111-123.
|
 |
|
|
|
|
 |
Y.Mukai,
T.Nakamura,
Y.Yoshioka,
H.Shibata,
Y.Abe,
T.Nomura,
M.Taniai,
T.Ohta,
S.Nakagawa,
S.Tsunoda,
H.Kamada,
Y.Yamagata,
and
Y.Tsutsumi
(2009).
Fast binding kinetics and conserved 3D structure underlie the antagonistic activity of mutant TNF: useful information for designing artificial proteo-antagonists.
|
| |
J Biochem, 146,
167-172.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
Y.Mukai,
T.Nakamura,
Y.Yoshioka,
S.Tsunoda,
H.Kamada,
S.Nakagawa,
Y.Yamagata,
and
Y.Tsutsumi
(2009).
Crystallization and preliminary X-ray analysis of the tumour necrosis factor alpha-tumour necrosis factor receptor type 2 complex.
|
| |
Acta Crystallogr Sect F Struct Biol Cryst Commun, 65,
295-298.
|
 |
|
|
|
|
 |
K.Chattopadhyay,
U.A.Ramagopal,
M.Brenowitz,
S.G.Nathenson,
and
S.C.Almo
(2008).
Evolution of GITRL immune function: murine GITRL exhibits unique structural and biochemical properties within the TNF superfamily.
|
| |
Proc Natl Acad Sci U S A, 105,
635-640.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
S.Kleber,
I.Sancho-Martinez,
B.Wiestler,
A.Beisel,
C.Gieffers,
O.Hill,
M.Thiemann,
W.Mueller,
J.Sykora,
A.Kuhn,
N.Schreglmann,
E.Letellier,
C.Zuliani,
S.Klussmann,
M.Teodorczyk,
H.J.Gröne,
T.M.Ganten,
H.Sültmann,
J.Tüttenberg,
A.von Deimling,
A.Regnier-Vigouroux,
C.Herold-Mende,
and
A.Martin-Villalba
(2008).
Yes and PI3K bind CD95 to signal invasion of glioblastoma.
|
| |
Cancer Cell, 13,
235-248.
|
 |
|
|
|
|
 |
A.Hayashi,
T.Chiba,
H.Hayashi,
S.Sasayama,
T.Ishiguro,
and
K.Onozaki
(2007).
Synthesis of glycosylated human tumor necrosis factor alpha coupled with N-acetylneuraminic acid.
|
| |
Cancer Immunol Immunother, 56,
545-553.
|
 |
|
|
|
|
 |
H.Saito,
T.Kojima,
M.Takahashi,
W.C.Horne,
R.Baron,
T.Amagasa,
K.Ohya,
and
K.Aoki
(2007).
A tumor necrosis factor receptor loop peptide mimic inhibits bone destruction to the same extent as anti-tumor necrosis factor monoclonal antibody in murine collagen-induced arthritis.
|
| |
Arthritis Rheum, 56,
1164-1174.
|
 |
|
|
|
|
 |
J.A.Wells,
and
C.L.McClendon
(2007).
Reaching for high-hanging fruit in drug discovery at protein-protein interfaces.
|
| |
Nature, 450,
1001-1009.
|
 |
|
|
|
|
 |
K.Chattopadhyay,
U.A.Ramagopal,
A.Mukhopadhaya,
V.N.Malashkevich,
T.P.Dilorenzo,
M.Brenowitz,
S.G.Nathenson,
and
S.C.Almo
(2007).
Assembly and structural properties of glucocorticoid-induced TNF receptor ligand: Implications for function.
|
| |
Proc Natl Acad Sci U S A, 104,
19452-19457.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
R.S.Wallis
(2007).
Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma.
|
| |
J Investig Dermatol Symp Proc, 12,
16-21.
|
 |
|
|
|
|
 |
S.Datta,
and
R.R.Maclean
(2007).
Neurobiological mechanisms for the regulation of mammalian sleep-wake behavior: reinterpretation of historical evidence and inclusion of contemporary cellular and molecular evidence.
|
| |
Neurosci Biobehav Rev, 31,
775-824.
|
 |
|
|
|
|
 |
T.Kohno,
L.T.Tam,
S.R.Stevens,
and
J.S.Louie
(2007).
Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs.
|
| |
J Investig Dermatol Symp Proc, 12,
5-8.
|
 |
|
|
|
|
 |
C.Zhu,
X.Liu,
J.Feng,
W.Zhang,
B.Shen,
W.Ou'yang,
Y.Cao,
and
B.Jin
(2006).
Characterization of the neutralizing activity of three anti-human TNF monoclonal antibodies and prediction of their TNF epitopes by molecular modeling and mutant protein approach.
|
| |
Immunol Lett, 102,
177-183.
|
 |
|
|
|
|
 |
K.Aoki,
H.Saito,
C.Itzstein,
M.Ishiguro,
T.Shibata,
R.Blanque,
A.H.Mian,
M.Takahashi,
Y.Suzuki,
M.Yoshimatsu,
A.Yamaguchi,
P.Deprez,
P.Mollat,
R.Murali,
K.Ohya,
W.C.Horne,
and
R.Baron
(2006).
A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss.
|
| |
J Clin Invest, 116,
1525-1534.
|
 |
|
|
|
|
 |
T.L.O'Loughlin,
D.N.Greene,
and
I.Matsumura
(2006).
Diversification and specialization of HIV protease function during in vitro evolution.
|
| |
Mol Biol Evol, 23,
764-772.
|
 |
|
|
|
|
 |
M.B.Yaffe
(2005).
X-ray crystallography and structural biology.
|
| |
Crit Care Med, 33,
S435-S440.
|
 |
|
|
|
|
 |
M.L.Narasimhan,
M.A.Coca,
J.Jin,
T.Yamauchi,
Y.Ito,
T.Kadowaki,
K.K.Kim,
J.M.Pardo,
B.Damsz,
P.M.Hasegawa,
D.J.Yun,
and
R.A.Bressan
(2005).
Osmotin is a homolog of mammalian adiponectin and controls apoptosis in yeast through a homolog of mammalian adiponectin receptor.
|
| |
Mol Cell, 17,
171-180.
|
 |
|
|
|
|
 |
N.Yan,
and
Y.Shi
(2005).
Mechanisms of apoptosis through structural biology.
|
| |
Annu Rev Cell Dev Biol, 21,
35-56.
|
 |
|
|
|
|
 |
R.Murali,
X.Cheng,
A.Berezov,
X.Du,
A.Schön,
E.Freire,
X.Xu,
Y.H.Chen,
and
M.I.Greene
(2005).
Disabling TNF receptor signaling by induced conformational perturbation of tryptophan-107.
|
| |
Proc Natl Acad Sci U S A, 102,
10970-10975.
|
 |
|
|
|
|
 |
S.Bouralexis,
D.M.Findlay,
and
A.Evdokiou
(2005).
Death to the bad guys: targeting cancer via Apo2L/TRAIL.
|
| |
Apoptosis, 10,
35-51.
|
 |
|
|
|
|
 |
T.Hehlgans,
and
K.Pfeffer
(2005).
The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games.
|
| |
Immunology, 115,
1.
|
 |
|
|
|
|
 |
G.Eissner,
W.Kolch,
and
P.Scheurich
(2004).
Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system.
|
| |
Cytokine Growth Factor Rev, 15,
353-366.
|
 |
|
|
|
|
 |
G.Zhang
(2004).
Tumor necrosis factor family ligand-receptor binding.
|
| |
Curr Opin Struct Biol, 14,
154-160.
|
 |
|
|
|
|
 |
S.D.Benson,
J.K.Bamford,
D.H.Bamford,
and
R.M.Burnett
(2004).
Does common architecture reveal a viral lineage spanning all three domains of life?
|
| |
Mol Cell, 16,
673-685.
|
 |
|
|
|
|
 |
T.Mori,
A.Oguro,
T.Ohtsu,
and
Y.Nakamura
(2004).
RNA aptamers selected against the receptor activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor receptor family.
|
| |
Nucleic Acids Res, 32,
6120-6128.
|
 |
|
|
|
|
 |
U.Kishore,
C.Gaboriaud,
P.Waters,
A.K.Shrive,
T.J.Greenhough,
K.B.Reid,
R.B.Sim,
and
G.J.Arlaud
(2004).
C1q and tumor necrosis factor superfamily: modularity and versatility.
|
| |
Trends Immunol, 25,
551-561.
|
 |
|
|
|
|
 |
Y.Liu,
L.H.Cheung,
J.W.Marks,
and
M.G.Rosenblum
(2004).
Recombinant single-chain antibody fusion construct targeting human melanoma cells and containing tumor necrosis factor.
|
| |
Int J Cancer, 108,
549-557.
|
 |
|
|
|
|
 |
Y.Yoshioka
(2004).
[Creation of functional muteins using phage libraries for pharmacoproteomic-based drug discovery and development of DDS]
|
| |
Yakugaku Zasshi, 124,
531-539.
|
 |
|
|
|
|
 |
K.Pfeffer
(2003).
Biological functions of tumor necrosis factor cytokines and their receptors.
|
| |
Cytokine Growth Factor Rev, 14,
185-191.
|
 |
|
|
|
|
 |
Y.Liu,
X.Hong,
J.Kappler,
L.Jiang,
R.Zhang,
L.Xu,
C.H.Pan,
W.E.Martin,
R.C.Murphy,
H.B.Shu,
S.Dai,
and
G.Zhang
(2003).
Ligand-receptor binding revealed by the TNF family member TALL-1.
|
| |
Nature, 423,
49-56.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
A.Ashkenazi
(2002).
Targeting death and decoy receptors of the tumour-necrosis factor superfamily.
|
| |
Nat Rev Cancer, 2,
420-430.
|
 |
|
|
|
|
 |
D.A.Oren,
Y.Li,
Y.Volovik,
T.S.Morris,
C.Dharia,
K.Das,
O.Galperina,
R.Gentz,
and
E.Arnold
(2002).
Structural basis of BLyS receptor recognition.
|
| |
Nat Struct Biol, 9,
288-292.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
G.H.Nam,
and
K.Y.Choi
(2002).
Association of human tumor necrosis factor-related apoptosis inducing ligand with membrane upon acidification.
|
| |
Eur J Biochem, 269,
5280-5287.
|
 |
|
|
|
|
 |
J.L.Bodmer,
P.Schneider,
and
J.Tschopp
(2002).
The molecular architecture of the TNF superfamily.
|
| |
Trends Biochem Sci, 27,
19-26.
|
 |
|
|
|
|
 |
B.Chackerian,
D.R.Lowy,
and
J.T.Schiller
(2001).
Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies.
|
| |
J Clin Invest, 108,
415-423.
|
 |
|
|
|
|
 |
C.J.Capini,
M.W.Richardson,
H.Hendel,
A.Sverstiuk,
J.Mirchandani,
E.G.Régulier,
K.Khalili,
J.F.Zagury,
and
J.Rappaport
(2001).
Autoantibodies to TNFalpha in HIV-1 infection: prospects for anti-cytokine vaccine therapy.
|
| |
Biomed Pharmacother, 55,
23-31.
|
 |
|
|
|
|
 |
R.M.Locksley,
N.Killeen,
and
M.J.Lenardo
(2001).
The TNF and TNF receptor superfamilies: integrating mammalian biology.
|
| |
Cell, 104,
487-501.
|
 |
|
|
|
|
 |
Y.Chen,
S.S.Molloy,
L.Thomas,
J.Gambee,
H.P.Bächinger,
B.Ferguson,
J.Zonana,
G.Thomas,
and
N.P.Morris
(2001).
Mutations within a furin consensus sequence block proteolytic release of ectodysplasin-A and cause X-linked hypohidrotic ectodermal dysplasia.
|
| |
Proc Natl Acad Sci U S A, 98,
7218-7223.
|
 |
|
|
|
|
 |
C.Zhou,
G.Shen,
H.Zhu,
J.Yang,
Y.Zhang,
J.Feng,
and
B.Shen
(2000).
Construction and analysis of three-dimensional graphic model of single-chain Fv derived from an anti-human placental acidic isoferritin monoclonal antibody by computer.
|
| |
J Tongji Med Univ, 20,
23-25.
|
 |
|
|
|
|
 |
E.Y.Jones
(2000).
The tumour necrosis factor receptor family: life or death choices.
|
| |
Curr Opin Struct Biol, 10,
644-648.
|
 |
|
|
|
|
 |
H.T.Idriss,
and
J.H.Naismith
(2000).
TNF alpha and the TNF receptor superfamily: structure-function relationship(s).
|
| |
Microsc Res Tech, 50,
184-195.
|
 |
|
|
|
|
 |
H.Ye,
and
H.Wu
(2000).
Thermodynamic characterization of the interaction between TRAF2 and tumor necrosis factor receptor peptides by isothermal titration calorimetry.
|
| |
Proc Natl Acad Sci U S A, 97,
8961-8966.
|
 |
|
|
|
|
 |
S.G.Hymowitz,
M.P.O'Connell,
M.H.Ultsch,
A.Hurst,
K.Totpal,
A.Ashkenazi,
A.M.de Vos,
and
R.F.Kelley
(2000).
A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL.
|
| |
Biochemistry, 39,
633-640.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.J.Newman,
B.Bond,
B.Crook,
J.Darker,
C.Edge,
and
P.R.Maycox
(2000).
Neuron-specific localisation of the TR3 death receptor in Alzheimer's disease.
|
| |
Brain Res, 857,
131-140.
|
 |
|
|
|
|
 |
S.W.Fesik
(2000).
Insights into programmed cell death through structural biology.
|
| |
Cell, 103,
273-282.
|
 |
|
|
|
|
 |
D.R.Westhead,
T.W.Slidel,
T.P.Flores,
and
J.M.Thornton
(1999).
Protein structural topology: Automated analysis and diagrammatic representation.
|
| |
Protein Sci, 8,
897-904.
|
 |
|
|
|
|
 |
F.Mancini,
C.M.Toro,
M.Mabilia,
M.Giannangeli,
M.Pinza,
and
C.Milanese
(1999).
Inhibition of tumor necrosis factor-alpha (TNF-alpha)/TNF-alpha receptor binding by structural analogues of suramin.
|
| |
Biochem Pharmacol, 58,
851-859.
|
 |
|
|
|
|
 |
K.J.Baeyens,
H.L.De Bondt,
A.Raeymaekers,
W.Fiers,
and
C.J.De Ranter
(1999).
The structure of mouse tumour-necrosis factor at 1.4 A resolution: towards modulation of its selectivity and trimerization.
|
| |
Acta Crystallogr D Biol Crystallogr, 55,
772-778.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
N.S.Postma,
R.C.Hermsen,
D.J.Crommelin,
W.M.Eling,
and
J.Zuidema
(1999).
Thiolated recombinant human tumor necrosis factor-alpha protects against Plasmodium berghei K173-induced experimental cerebral malaria in mice.
|
| |
Antimicrob Agents Chemother, 43,
1027-1033.
|
 |
|
|
|
|
 |
P.Schneider,
R.Schwenzer,
E.Haas,
F.Mühlenbeck,
G.Schubert,
P.Scheurich,
J.Tschopp,
and
H.Wajant
(1999).
TWEAK can induce cell death via endogenous TNF and TNF receptor 1.
|
| |
Eur J Immunol, 29,
1785-1792.
|
 |
|
|
|
|
 |
S.G.Hymowitz,
H.W.Christinger,
G.Fuh,
M.Ultsch,
M.O'Connell,
R.F.Kelley,
A.Ashkenazi,
and
A.M.de Vos
(1999).
Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5.
|
| |
Mol Cell, 4,
563-571.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.S.Cha,
H.C.Shin,
K.Y.Choi,
and
B.H.Oh
(1999).
Expression, purification and crystallization of recombinant human TRAIL.
|
| |
Acta Crystallogr D Biol Crystallogr, 55,
1101-1104.
|
 |
|
|
|
|
 |
S.S.Cha,
M.S.Kim,
Y.H.Choi,
B.J.Sung,
N.K.Shin,
H.C.Shin,
Y.C.Sung,
and
B.H.Oh
(1999).
2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity.
|
| |
Immunity, 11,
253-261.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.S.Pullen,
M.E.Labadia,
R.H.Ingraham,
S.M.McWhirter,
D.S.Everdeen,
T.Alber,
J.J.Crute,
and
M.R.Kehry
(1999).
High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization.
|
| |
Biochemistry, 38,
10168-10177.
|
 |
|
|
|
|
 |
D.N.Mauri,
R.Ebner,
R.I.Montgomery,
K.D.Kochel,
T.C.Cheung,
G.L.Yu,
S.Ruben,
M.Murphy,
R.J.Eisenberg,
G.H.Cohen,
P.G.Spear,
and
C.F.Ware
(1998).
LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator.
|
| |
Immunity, 8,
21-30.
|
 |
|
|
|
|
 |
G.Lu,
Z.H.Zhou,
M.L.Baker,
J.Jakana,
D.Cai,
X.Wei,
S.Chen,
X.Gu,
and
W.Chiu
(1998).
Structure of double-shelled rice dwarf virus.
|
| |
J Virol, 72,
8541-8549.
|
 |
|
|
|
|
 |
J.Singh,
E.Garber,
H.Van Vlijmen,
M.Karpusas,
Y.M.Hsu,
Z.Zheng,
J.H.Naismith,
and
D.Thomas
(1998).
The role of polar interactions in the molecular recognition of CD40L with its receptor CD40.
|
| |
Protein Sci, 7,
1124-1135.
|
 |
|
|
|
|
 |
L.Shapiro,
and
P.E.Scherer
(1998).
The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor.
|
| |
Curr Biol, 8,
335-338.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
T.A.Tran,
B.V.Kallakury,
R.A.Ambros,
and
J.S.Ross
(1998).
Prognostic significance of tumor necrosis factors and their receptors in nonsmall cell lung carcinoma.
|
| |
Cancer, 83,
276-282.
|
 |
|
|
|
|
 |
D.J.Underwood,
and
K.Prendergast
(1997).
Getting it together: signal transduction in G-protein coupled receptors by association of receptor domains.
|
| |
Chem Biol, 4,
239-248.
|
 |
|
|
|
|
 |
M.Bergdoll,
M.H.Remy,
C.Cagnon,
J.M.Masson,
and
P.Dumas
(1997).
Proline-dependent oligomerization with arm exchange.
|
| |
Structure, 5,
391-401.
|
 |
|
|
|
|
 |
W.Takasaki,
Y.Kajino,
K.Kajino,
R.Murali,
and
M.I.Greene
(1997).
Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNF alpha binding to its receptor.
|
| |
Nat Biotechnol, 15,
1266-1270.
|
 |
|
|
|
|
 |
W.Tang,
T.Xi,
B.Wang,
D.Guo,
X.Xu,
and
D.Zhu
(1997).
Prediction of mutant activity and its application in molecular design of tumor necrosis factor-alpha.
|
| |
Sci China C Life Sci, 40,
1-9.
|
 |
|
|
|
|
 |
C.M.Hill,
and
J.Lunec
(1996).
The TNF-ligand and receptor superfamilies: controllers of immunity and the Trojan horses of autoimmune disease?
|
| |
Mol Aspects Med, 17,
455-509.
|
 |
|
|
|
|
 |
H.J.Gruss
(1996).
Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily.
|
| |
Int J Clin Lab Res, 26,
143-159.
|
 |
|
|
|
|
 |
P.Tang,
Hung M-C,
and
J.Klostergaard
(1996).
Human pro-tumor necrosis factor is a homotrimer.
|
| |
Biochemistry, 35,
8216-8225.
|
 |
|
|
|
|
 |
R.L.Baldwin,
M.L.Stolowitz,
L.Hood,
and
B.J.Wisnieski
(1996).
Structural changes of tumor necrosis factor alpha associated with membrane insertion and channel formation.
|
| |
Proc Natl Acad Sci U S A, 93,
1021-1026.
|
 |
|
|
|
|
 |
R.Takakura-Yamamoto,
S.Yamamoto,
S.Fukuda,
and
M.Kurimoto
(1996).
O-glycosylated species of natural human tumor-necrosis factor-alpha.
|
| |
Eur J Biochem, 235,
431-437.
|
 |
|
|
|
|
 |
T.M.Foy,
A.Aruffo,
J.Bajorath,
J.E.Buhlmann,
and
R.J.Noelle
(1996).
Immune regulation by CD40 and its ligand GP39.
|
| |
Annu Rev Immunol, 14,
591-617.
|
 |
|
|
|
|
 |
U.Reineke,
R.Sabat,
A.Kramer,
R.D.Stigler,
M.Seifert,
T.Michel,
H.D.Volk,
and
J.Schneider-Mergener
(1996).
Mapping protein-protein contact sites using cellulose-bound peptide scans.
|
| |
Mol Divers, 1,
141-148.
|
 |
|
|
|
|
 |
Y.Kato,
T.Muto,
T.Tomura,
H.Tsumura,
H.Watarai,
T.Mikayama,
K.Ishizaka,
and
R.Kuroki
(1996).
The crystal structure of human glycosylation-inhibiting factor is a trimeric barrel with three 6-stranded beta-sheets.
|
| |
Proc Natl Acad Sci U S A, 93,
3007-3010.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.Corti,
S.Merli,
L.Bagnasco,
F.D'Ambrosio,
M.Marino,
and
G.Cassani
(1995).
Identification of two forms (31-33 and 48 kD) of the urinary soluble p55 tumor necrosis factor receptor that are differentially N- and O-glycosylated.
|
| |
J Interferon Cytokine Res, 15,
143-152.
|
 |
|
|
|
|
 |
B.S.Chapman,
and
I.D.Kuntz
(1995).
Modeled structure of the 75-kDa neurotrophin receptor.
|
| |
Protein Sci, 4,
1696-1707.
|
 |
|
|
|
|
 |
K.Nagahira,
Y.Fukuda,
M.Terakawa,
J.Hashino,
T.Nasu,
H.Nakazato,
and
T.Nakanishi
(1995).
Epitope mapping of monoclonal antibodies to tumor necrosis factor-alpha by synthetic peptide approach.
|
| |
Immunol Lett, 46,
135-141.
|
 |
|
|
|
|
 |
M.Karpusas,
Y.M.Hsu,
J.H.Wang,
J.Thompson,
S.Lederman,
L.Chess,
and
D.Thomas
(1995).
2 A crystal structure of an extracellular fragment of human CD40 ligand.
|
| |
Structure, 3,
1031-1039.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.Schuchmann,
S.Hess,
P.Bufler,
C.Brakebusch,
D.Wallach,
A.Porter,
G.Riethmüller,
and
H.Engelmann
(1995).
Functional discrepancies between tumor necrosis factor and lymphotoxin alpha explained by trimer stability and distinct receptor interactions.
|
| |
Eur J Immunol, 25,
2183-2189.
|
 |
|
|
|
|
 |
M.Tanaka,
T.Suda,
T.Takahashi,
and
S.Nagata
(1995).
Expression of the functional soluble form of human fas ligand in activated lymphocytes.
|
| |
EMBO J, 14,
1129-1135.
|
 |
|
|
|
|
 |
R.Hlodan,
and
R.H.Pain
(1995).
The folding and assembly pathway of tumour necrosis factor TNF alpha, a globular trimeric protein.
|
| |
Eur J Biochem, 231,
381-387.
|
 |
|
|
|
|
 |
S.Hess,
R.Kurrle,
L.Lauffer,
G.Riethmüller,
and
H.Engelmann
(1995).
A cytotoxic CD40/p55 tumor necrosis factor receptor hybrid detects CD40 ligand on herpesvirus saimiri-transformed T cells.
|
| |
Eur J Immunol, 25,
80-86.
|
 |
|
|
|
|
 |
B.Beutler,
and
C.Van Huffel
(1994).
An evolutionary and functional approach to the TNF receptor/ligand family.
|
| |
Ann N Y Acad Sci, 730,
118-133.
|
 |
|
|
|
|
 |
D.Cosman
(1994).
A family of ligands for the TNF receptor superfamily.
|
| |
Stem Cells, 12,
440-455.
|
 |
|
|
|
|
 |
J.A.Wells
(1994).
Structural and functional basis for hormone binding and receptor oligomerization.
|
| |
Curr Opin Cell Biol, 6,
163-173.
|
 |
|
|
|
|
 |
O.Rekdal,
Z.Konopski,
J.S.Svendsen,
J.O.Winberg,
T.Espevik,
and
B.Osterud
(1994).
The TNF Receptors p55 and p75 Mediate Chemotaxis of PMN Induced by TNFalpha and a TNFalpha 36-62 Peptide.
|
| |
Mediators Inflamm, 3,
347-352.
|
 |
|
|
|
|
 |
P.R.Baum,
R.B.Gayle,
F.Ramsdell,
S.Srinivasan,
R.A.Sorensen,
M.L.Watson,
M.F.Seldin,
E.Baker,
G.R.Sutherland,
and
K.N.Clifford
(1994).
Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34.
|
| |
EMBO J, 13,
3992-4001.
|
 |
|
|
|
|
 |
T.J.Evans,
D.Moyes,
A.Carpenter,
R.Martin,
H.Loetscher,
W.Lesslauer,
and
J.Cohen
(1994).
Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis.
|
| |
J Exp Med, 180,
2173-2179.
|
 |
|
|
|
|
 |
T.Takahashi,
M.Tanaka,
C.I.Brannan,
N.A.Jenkins,
N.G.Copeland,
T.Suda,
and
S.Nagata
(1994).
Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand.
|
| |
Cell, 76,
969-976.
|
 |
|
|
|
|
 |
A.Aruffo,
M.Farrington,
D.Hollenbaugh,
X.Li,
A.Milatovich,
S.Nonoyama,
J.Bajorath,
L.S.Grosmaire,
R.Stenkamp,
and
M.Neubauer
(1993).
The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome.
|
| |
Cell, 72,
291-300.
|
 |
|
|
|
|
 |
B.L.Kagan,
T.Mirzabekov,
D.Munoz,
R.L.Baldwin,
and
B.Wisnieski
(1993).
The role of channel formation in the mechanism of action of tumor necrosis factors.
|
| |
Ann N Y Acad Sci, 707,
317-327.
|
 |
|
|
|
|
 |
C.A.Smith,
H.J.Gruss,
T.Davis,
D.Anderson,
T.Farrah,
E.Baker,
G.R.Sutherland,
C.I.Brannan,
N.G.Copeland,
and
N.A.Jenkins
(1993).
CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF.
|
| |
Cell, 73,
1349-1360.
|
 |
|
|
|
|
 |
D.W.Banner,
A.D'Arcy,
W.Janes,
R.Gentz,
H.J.Schoenfeld,
C.Broger,
H.Loetscher,
and
W.Lesslauer
(1993).
Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation.
|
| |
Cell, 73,
431-445.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.Bajorath,
R.Stenkamp,
and
A.Aruffo
(1993).
Knowledge-based model building of proteins: concepts and examples.
|
| |
Protein Sci, 2,
1798-1810.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
R.G.Goodwin,
W.S.Din,
T.Davis-Smith,
D.M.Anderson,
S.D.Gimpel,
T.A.Sato,
C.R.Maliszewski,
C.I.Brannan,
N.G.Copeland,
and
N.A.Jenkins
(1993).
Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor.
|
| |
Eur J Immunol, 23,
2631-2641.
|
 |
|
|
|
|
 |
R.S.Sidhu,
and
A.P.Bollon
(1993).
Tumor necrosis factor activities and cancer therapy--a perspective.
|
| |
Pharmacol Ther, 57,
79.
|
 |
|
|
|
|
 |
T.Suda,
T.Takahashi,
P.Golstein,
and
S.Nagata
(1993).
Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family.
|
| |
Cell, 75,
1169-1178.
|
 |
|
|
|
|
 |
Y.Mitsui,
T.Senda,
T.Shimazu,
S.Matsuda,
and
J.Utsumi
(1993).
Structural, functional and evolutionary implications of the three-dimensional crystal structure of murine interferon-beta.
|
| |
Pharmacol Ther, 58,
93.
|
 |
|
|
|
|
 |
A.Brass,
K.E.Kadler,
J.T.Thomas,
M.E.Grant,
and
R.P.Boot-Handford
(1992).
The fibrillar collagens, collagen VIII, collagen X and the C1q complement proteins share a similar domain in their C-terminal non-collagenous regions.
|
| |
FEBS Lett, 303,
126-128.
|
 |
|
|
|
|
 |
D.Aderka,
H.Engelmann,
Y.Maor,
C.Brakebusch,
and
D.Wallach
(1992).
Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors.
|
| |
J Exp Med, 175,
323-329.
|
 |
|
|
|
|
 |
D.Hollenbaugh,
L.S.Grosmaire,
C.D.Kullas,
N.J.Chalupny,
S.Braesch-Andersen,
R.J.Noelle,
I.Stamenkovic,
J.A.Ledbetter,
and
A.Aruffo
(1992).
The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity.
|
| |
EMBO J, 11,
4313-4321.
|
 |
|
|
|
|
 |
J.Rothe,
G.Gehr,
H.Loetscher,
and
W.Lesslauer
(1992).
Tumor necrosis factor receptors--structure and function.
|
| |
Immunol Res, 11,
81-90.
|
 |
|
|
|
|
 |
M.D.Walkinshaw
(1992).
Protein targets for structure-based drug design.
|
| |
Med Res Rev, 12,
317-372.
|
 |
|
|
|
|
 |
R.H.Stiemer,
U.Westenfelder,
H.Gausepohl,
M.Mirshahi,
A.Gundt,
R.W.Frank,
and
D.N.Männel
(1992).
A common epitope on human tumor necrosis factor alpha and the autoantigen 'S-antigen/arrestin' induces TNF-alpha production.
|
| |
J Autoimmun, 5,
15-26.
|
 |
|
|
|
|
 |
T.Senda,
T.Shimazu,
S.Matsuda,
G.Kawano,
H.Shimizu,
K.T.Nakamura,
and
Y.Mitsui
(1992).
Three-dimensional crystal structure of recombinant murine interferon-beta.
|
| |
EMBO J, 11,
3193-3201.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.Ashkenazi,
S.A.Marsters,
D.J.Capon,
S.M.Chamow,
I.S.Figari,
D.Pennica,
D.V.Goeddel,
M.A.Palladino,
and
D.H.Smith
(1991).
Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin.
|
| |
Proc Natl Acad Sci U S A, 88,
10535-10539.
|
 |
|
|
|
|
 |
A.D.Nash,
G.J.Barcham,
M.R.Brandon,
and
A.E.Andrews
(1991).
Molecular cloning, expression and characterization of ovine TNF alpha.
|
| |
Immunol Cell Biol, 69,
273-283.
|
 |
|
|
|
|
 |
B.B.Aggarwal
(1991).
Structure of tumor necrosis factor and its receptor.
|
| |
Biotherapy, 3,
113-120.
|
 |
|
|
|
|
 |
G.Camussi,
E.Albano,
C.Tetta,
and
F.Bussolino
(1991).
The molecular action of tumor necrosis factor-alpha.
|
| |
Eur J Biochem, 202,
3.
|
 |
|
|
|
|
 |
J.D.Zhang,
L.S.Cousens,
P.J.Barr,
and
S.R.Sprang
(1991).
Three-dimensional structure of human basic fibroblast growth factor, a structural homolog of interleukin 1 beta.
|
| |
Proc Natl Acad Sci U S A, 88,
3446-3450.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.H.Riazance-Lawrence,
A.Toumadje,
and
W.C.Johnson
(1991).
The circular dichroism of tumor necrosis factor-alpha: measurement into the vacuum UV and analysis for secondary structure.
|
| |
Chirality, 3,
254-256.
|
 |
|
|
|
|
 |
S.D.Gillies,
D.Young,
K.M.Lo,
S.F.Foley,
and
R.A.Reisfeld
(1991).
Expression of genetically engineered immunoconjugates of lymphotoxin and a chimeric anti-ganglioside GD2 antibody.
|
| |
Hybridoma, 10,
347-356.
|
 |
|
|
|
|
 |
W.Fiers
(1991).
Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level.
|
| |
FEBS Lett, 285,
199-212.
|
 |
|
|
|
|
 |
X.Van Ostade,
J.Tavernier,
T.Prangé,
and
W.Fiers
(1991).
Localization of the active site of human tumour necrosis factor (hTNF) by mutational analysis.
|
| |
EMBO J, 10,
827-836.
|
 |
|
|
|
|
 |
A.E.Postlethwaite,
and
J.M.Seyer
(1990).
Stimulation of fibroblast chemotaxis by human recombinant tumor necrosis factor alpha (TNF-alpha) and a synthetic TNF-alpha 31-68 peptide.
|
| |
J Exp Med, 172,
1749-1756.
|
 |
|
|
|
|
 |
A.Himmler,
I.Maurer-Fogy,
M.Krönke,
P.Scheurich,
K.Pfizenmaier,
M.Lantz,
I.Olsson,
R.Hauptmann,
C.Stratowa,
and
G.R.Adolf
(1990).
Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein.
|
| |
DNA Cell Biol, 9,
705-715.
|
 |
|
|
|
|
 |
P.Seckinger,
J.H.Zhang,
B.Hauptmann,
and
J.M.Dayer
(1990).
Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: evidence of immunological cross-reactivity with the TNF receptor.
|
| |
Proc Natl Acad Sci U S A, 87,
5188-5192.
|
 |
|
|
|
|
 |
S.R.Sprang
(1990).
The divergent receptors for TNF.
|
| |
Trends Biochem Sci, 15,
366-368.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
|